Main menu
  1. Home
  2.  » 
  3. About Us
  4.  » 
  5. Our Scientists
  6.  » Nicolas Thurin, Ph.D.

Nicolas Thurin, Ph.D.


Nicolas Thurin, Ph.D., is Director, Scientific Community & Office based at Catalent’s Brussels facility, which focuses on the manufacturing of sterile injectables.

Nicolas has a broad background in molecular biology, analytical chemistry, analytical product development, and GMP sterile manufacturing of small molecules and large molecules.

Since 2011, Nicolas has managed more than 100 complex scientific projects as an Analytical Product Development Manager. He was also QC-Chemistry manager. “Scientific Excellence and Operational Excellence are deeply connected” according to him.

Since 2017, Nicolas has been leading Catalent’s analytical network, working with 1,100 scientists from 26 laboratories to drive scientific excellence.

Prior to joining Catalent 8 years ago, Nicolas was a researcher at the University of Brussels, where he focused his multi-disciplinary research on the evolution of reproductive strategies in animal societies. Nicolas received a Master of Science in Biology from the University of Grenoble in France and his Ph.D. in Molecular Biology from the University of Brussels in Belgium.

Get to know this Catalyst in drug product development. Discover what drives his commitment to develop new products with the best outcomes for patients and access his works to help you develop better products for your patients. Learn how Nicolas leverages the Catalent Scientific network to overcome difficult development challenges.

Key Expertise: Analytical Science

Connect with Nicolas Thurin on LinkedIn


You have led a Product Development laboratory for the past 8 years, what drives you to develop new products?

Providing the best treatment to patients remains my first objective. This entails supporting our customers’ expedient market launches for new drug products while ensuring the highest level of quality. Every project is a new challenge as each molecule presents unique testing requirements. To help me tackle these development challenges, I work with a team of brilliant scientists in Brussels who have a wide array of impressive expertise. I rely on support from Catalent’s global network of 1,500+ scientists if we don’t have specific expertise locally. With the expertise of this global network, there are almost no barriers to the development of new products that Catalent scientists cannot overcome.

Tell me more about Catalent’s scientific community. How can it overcome obstacles in developing new drug products?

An important strength of Catalent is its diversity in facilities that manufacture products, advanced technologies, and scientists. The synergies created by connecting our scientists through a Scientific Resource Center reinforce our capacity to develop the best treatments for patients. Through this platform, our scientists share the most recent innovations, operational excellence improvements, and information on updated guidelines. They have full access to impactful scientific journals to stay informed on the latest technical and scientific advancements. The Scientific Resource Center benefits clients by connecting every Catalent scientist to a large community of Subject Matter Experts that, together, can overcome the most difficult challenges related to the development of life-saving treatments.

The Brussels facility manufactures sterile injectables. Could you share with us an example of an analytical method specific to these products?

We test the Container Closure Integrity (CCI) on prefilled syringes at the Brussels facility. USP chapter <1207> introduced new guidelines in 2017 that provide clear guidance on how to do this. It was a very hot topic for our customers as it introduced a lot of new requirements, and the traditional method was no longer applicable. It is very important to consider the integrity of the drug product from its design to its administration to the patient.  At Catalent Brussels, we have strong expertise on Container Closure Integrity Testing (CCIT), different technologies available, and can advise on the best practices to be compliant with regulatory requirements. We have developed many specific methods, and we work with our customers as a reliable partner to ensure better treatments for patients.

As you have managed both Analytical Product Development and Quality Control, what is your vision of these two departments?

The primary aim of both Analytical Product Development and Quality Control is the reliable delivery of a high-quality treatment to patients. Analytical Product Development must provide Quality Control with robust reliable methods and scientific solutions to ensure the quality of the drugs. Quality Control is an operational department that needs both to gather a lot of high-quality data at short term and to be adaptive to support manufacturing planning. You cannot deliver a reliable treatment without a sound scientific foundation, and you need operational efficiency to execute good science. Scientific Excellence and Operational Excellence are deeply connected.